Neurocrine Biosciences' shares rose 9.7% after the quarter, driven by better-than-expected revenue growth led by INGREZZA’s continued double-digit expansion and solid execution across the commercial portfolio.

• Total Q1 net product sales surpassed $800 million for the first time, marking 44% year-over-year growth.
• INGREZZA sales grew 20% year-over-year to $657 million, reflecting robust volume growth and record new patient starts; adjusted for a calendar difference, growth was about 11%.
• CRENESSITY sales reached $153 million, supported by consistent new patient enrollment and favorable reimbursement despite slight co-pay reset pressures.
• Management reaffirmed full-year INGREZZA guidance of $2.7 billion to $2.8 billion and anticipates providing updates after the first half of 2026.
• Pipeline development continues with plans for multiple Phase I and II programs in 2026 and key data readouts in 2027, supporting long-term growth prospects.